switching from semaglutide to retatrutide vs. semaglutide: A head-to-head comparison Two powerful options, one goal:

While orforglipron addresses exclusively the GLP-1 pathway, retatrutide combines the incretin-mediated pathways of GIP and GLP-1 with the glucagon-mediated component, which in research is associated with increased energy expenditure

the gastrointestinal side effects and visible weight loss typical of this class threaten the integrity of trials with subjective outcomes, which again argues for objective endpoints

Under standard FDA review timelines, a decision is expected in late 2026

82 Furthermore, oral carnitine, and its derivative acetyl-L-carnitine, have both neuroprotective 83, 84 and coloprotective properties

So it's more so a way to optimize an already great routine to get the best results